FeesSafety
Pluang+

AI boosts AstraZeneca's drug development speed and trial success rates, says CEO Pascal Soriot

Market News
06 Jun 2026, 01:26 WIB
CNBC
View Source
Bullish
AI boosts AstraZeneca's drug development speed and trial success rates, says CEO Pascal Soriot

AstraZeneca CEO Pascal Soriot highlighted that artificial intelligence (AI) is significantly enhancing the company's ability to develop medicines faster and make smarter research decisions. AI tools help identify promising drug targets, optimize molecules to reduce side effects, and improve the chances of success in costly clinical trials. Through partnerships with Tempus AI and Pathos, AstraZeneca uses AI models to analyze clinical and laboratory data, increasing the probability of success in late-stage trials and improving productivity. This advancement could save hundreds of millions of dollars per trial and accelerate innovation across AstraZeneca's drug pipeline.

More News (AZN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App